Gregg Gilbert
Stock Analyst at Truist Securities
(1.50)
# 3,158
Out of 4,827 analysts
91
Total ratings
50%
Success rate
-3.73%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $10.92 | +55.68% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $27.64 | +33.86% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $47.11 | +78.31% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $757.36 | -30.68% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $10.40 | +25.00% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $17.54 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $78.03 | +19.18% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $13.94 | +244.46% | 2 | Feb 2, 2021 | |
| CHRS Coherus BioSciences | Initiates: Buy | $26 | $0.98 | +2,558.21% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.70 | +21,328.57% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $26.60 | +193.29% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $161.08 | -51.58% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $18.20 | -1.07% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $106.00 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $99.02 | +76.73% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $185.14 | -64.35% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $10.92
Upside: +55.68%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $27.64
Upside: +33.86%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $47.11
Upside: +78.31%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $757.36
Upside: -30.68%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $10.40
Upside: +25.00%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $17.54
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $78.03
Upside: +19.18%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $13.94
Upside: +244.46%
Coherus BioSciences
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $0.98
Upside: +2,558.21%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.70
Upside: +21,328.57%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $26.60
Upside: +193.29%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $161.08
Upside: -51.58%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $18.20
Upside: -1.07%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $106.00
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $99.02
Upside: +76.73%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $185.14
Upside: -64.35%